Skip to main content

Table 3 Predictability of efficacy endpoints for an HBV DNA reduction threshold of ≤5 log 10 copies/mL vs. >5 log 10 copies/mL at Week 24

From: Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at Week 24

Endpoints Odds ratio 95% CI Pvalue
Treatment Year 1    
Maintained PCR negativity 0.650 (0.119, 3.541) 0.6183
Maintained ALT normalization 0.283 (0.032, 2.530) 0.2586
Maintained HBeAg loss 0.000 (0.000, >999.9) 0.9619
Maintained HBeAg seroconversion 0.000 (0.000, >999.9) 0.9517
Treatment Year 2    
Maintained PCR negativity 0.075 (0.007, 0.765) 0.0288
Maintained ALT normalization 0.349 (0.056, 2.174) 0.2592
Maintained HBeAg loss 0.339 (0.032, 3.616) 0.3707
Maintained HBeAg seroconversion 0.368 (0.033, 4.085) 0.4156
Cumulative treatment-emergent resistance 9.593 (1.387, 66.347) 0.0219
Treatment Year 3    
Maintained PCR negativity 0.056 (0.005, 0.623) 0.0190
Maintained ALT normalization 0.313 (0.053, 1.855) 0.2010
Maintained HBeAg loss 0.124 (0.012, 1.300) 0.0816
Maintained HBeAg seroconversion 0.313 (0.030, 3.231) 0.3295
Cumulative treatment-emergent resistance >999.9 (0.000, >999.9) 0.9681
Treatment Year 4    
Maintained PCR negativity 0.053 (0.005, 0.584) 0.0164
Maintained ALT normalization 0.195 (0.032, 1.1980 0.0776
Maintained HBeAg loss 0.147 (0.015, 1.4530 0.1009
Maintained HBeAg seroconversion 0.219 (0.022, 2.209) 0.1976
Cumulative treatment-emergent resistance >999.9 (0.000, >999.9) 0.9681